Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

103 Results
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role: Lead Sponsor
Terminated
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H
Study participants will receive the following treatment: Day -5 to -2...Fludarabine 30mg/m2* and CAMPATH** 1H 10mg IV Day -1.........Day of rest Day 0..........Stem cell transplant (infusion) Where possible, patients will …
Baylor Role: Lead Sponsor
Terminated
Stem Cell Transplant for Hematologic Diseases
Before treatment begins, stem cells will be collected from the donor's blood or bone marrow. The stem cells will be collected and frozen before we start to give the patient …
Baylor Role: Lead Sponsor
Completed
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation
Patients will receive cytosine arabinoside (3g/m^2) IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide (45mg/kg) will be given on Day -7 and Day …
Baylor Role: Lead Sponsor
Completed
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although …
Baylor Role: Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role: Lead Sponsor
Unknown Status
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
PROTOCOL OUTLINE: Patients are assigned to one of 6 study groups. Patients receive infusions of stable isotope tracers: [15N]urea IV beginning at -12 hours and continuing over 22 hours to …
Baylor Role: Collaborator
Completed
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
Before starting in the treatment part of this study, leukemia cells and skin fibroblasts will be collected from the patient - called "procurement" - to allow us to make the …
Baylor Role: Lead Sponsor
Completed
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer
The development of a clinical trial for gene therapy in prostate cancer will be coordinated with our collaborators at Baylor involved in similar studies in order to facilitate the approval …
Baylor Role: Lead Sponsor
Completed
Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
The investigators have grown neuroblastoma cells in the laboratory and put into them two specially produced mouse viruses (retroviruses) that carry the lymphotactin and the IL-2 gene. These lymphotactin and …
Baylor Role: Lead Sponsor